Jasper Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
JSPR$14.75-9.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows used in operating activities | ||
| Net loss | $(64,465) | $(37,685) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization expense | 1,108 | 975 |
| Non-cash lease expense | 419 | 335 |
| Stock-based compensation expense | 5,211 | 4,091 |
| Change in fair value of common stock warrant liability | 575 | (7,200) |
| Change in fair value of earnout liability | (18) | (5,725) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 767 | 312 |
| Other receivables | 663 | (663) |
| Other non-current assets | (584) | (114) |
| Accounts payable | 2,381 | (2,151) |
| Accrued expenses and other current liabilities | 2,821 | 836 |
| Operating lease liability | (865) | (589) |
| Other non-current liabilities | (80) | 1,720 |
| Net cash used in operating activities | (52,067) | (45,858) |
| Cash flows used in investing activities | ||
| Purchases of property and equipment | (267) | (576) |
| Net cash used in investing activities | (267) | (576) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock through ATM and underwritten offerings, net | 101,479 | — |
| Proceeds from exercise of common stock options | 388 | 27 |
| Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plan | 64 | 28 |
| Taxes withheld and paid related to net settlement of equity awards | (960) | — |
| Net cash provided by financing activities | 100,971 | 55 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 48,637 | (46,379) |
| Cash, cash equivalents and restricted cash at beginning of the year | 38,667 | 85,046 |
| Cash, cash equivalents and restricted cash at end of the year | $87,304 | $38,667 |
| Supplemental and non-cash items reconciliations: | ||
| Reclassification of common stock warrant liability into additional paid-in capital | $725 | $— |
| Right-of-use asset obtained in exchange for lease liabilities | $— | $1,074 |
| Non-cash leasehold improvements | $— | $(281) |
| Letter of credit issued in connection with lease recognition | $— | $72 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.